Asthma and Therapeutics: Recombinant Therapies in Asthma
Tóm tắt
Numerous recombinant therapies are being investigated for the treatment of asthma. This report reviews the current status of several of these novel agents. Anti-immunoglobulin (Ig)E (omalizumab, Xolair) markedly inhibits all aspects of the allergen challenge in subjects who have reduction of free serum IgE to undetectable levels. Several clinical studies in atopic asthma have demonstrated benefit by improved symptoms and lung function and a reduction in corticosteroid requirements. Early use in atopic asthmatics may be even more effective. Several approaches target interleukin (IL)-4. Soluble IL-4 receptor has been shown to effectively replace inhaled corticosteroid; further studies are under way. Recombinant anti-IL-5 and recombinant IL-12 inhibit blood and sputum eosinophils and allergen-induced eosinophilia without any effect on airway responsiveness, allergen-induced airway responses, or allergen-induced airway hyperresponsiveness. Efalizumab, a recombinant antibody that inhibits lymphocyte trafficking, is effective in psoriasis. A bronchoprovocation study showed a reduction in allergen-induced late asthmatic response and allergen-induced eosinophilia, which suggests that it should be effective in clinical asthma. These exciting novel therapies provide not only promise of new therapies for asthma but also valuable tools for investigation of asthma mechanisms.
Tài liệu tham khảo
Cockcroft DW: Pharmacologic therapy for asthma: overview and historical perspective. J Clin Pharmacol. 1999, 39: 216-22.
Tiffeneau R, Beauvallet M: Epreuve de bron-choconstriction et de bronchodilation par aerosols. Bull Acad Med. 1945, 129: 165-8.
McPhedran A: Diseases of the bronchi. Modern Medicine: Its Theory and Practice: Vol III Infectious Disease -Diseases of the Respiratory Tract. Edited by: Osler W. 1907, Philadelphia: Lea Brothers, 636-722.
Boulet L-P, Becker A, Berube D: Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. Can Med Assoc J. 1999, 161 (Suppl 11): S1-61.
Barnes PJ: New directions in allergic diseases: mechanism-based anti-inflammatory therapies. J Allergy Clin Immunol. 2000, 106: 5-16. 10.1067/mai.2000.107930.
Ishizaka K, Ishizaka T: Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol. 1967, 99: 1187-98.
Cockcroft DW, Ruffin RE, Dolovich J, Hargreave FE: Allergen-induced increase in nonallergic bronchial reactivity. Clin Allergy. 1977, 7: 503-13. 10.1111/j.1365-2222.1977.tb01481.x.
de Monchy JGR, Kauffman HF, Venge P: Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis. 1985, 131: 373-6.
Dolovich J, Hargreave FE: The asthma syndrome: inciters, inducers, and host characteristics. Thorax. 1981, 36: 641-4. 10.1136/thx.36.9.614.
Cockcroft DW, Hargreave FE: Relationship between atopy and airway responsiveness. Bronchitis IV. Edited by: Sluiter HJ, Van der Lende R. 1988, Assen, The Netherlands: Van Gorcum, 23-32.
Peat JK, Salome CM, Woolcock AJ: Longitudinal changes in atopy during a 4-year period: relation to bronchial hyperresponsiveness and respiratory symptoms in a population sample of Australian schoolchildren. J Allergy Clin Immunol. 1990, 85: 65-74. 10.1016/0091-6749(90)90223-Q.
Warner JO: Bronchial hyperresponsiveness, atopy, airway inflammation, and asthma. Pediatr Allergy Immunol. 1998, 9: 56-60. 10.1111/j.1399-3038.1998.tb00304.x.
Lam S, Wong R, Yeung M: Nonspecific bronchial reactivity in occupational asthma. J Allergy Clin Immunol. 1979, 63: 28-34. 10.1016/0091-6749(79)90158-1.
Cockcroft DW, Murdock KY: Comparative effects of inhaled salbutamol, sodium cromoglycate and beclomethasone dipro-pionate on allergen-induced early asthmatic responses, late asthmatic responses and increased bronchial responsiveness to histamine. J Allergy Clin Immunol. 1987, 79: 734-40. 10.1016/0091-6749(87)90204-1.
Presta LG, Lahr SJ, Shields RL: Humanization of an antibody directed against IgE. J Immunol. 1993, 151: 2623-32.
Shields RL, Whether WR, Zioncheck K: Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol. 1995, 107: 308-12. 10.1159/000237010.
MacGlashan DW, Bochner BS, Adelman DC: Down-regulation of Fc(epsilon) RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997, 158: 1438-45.
Boulet L-P, Cockcroft DW: IgE-mediated response to allergen in the bronchoprovocation laboratory. Anti-IgE and allergic disease. Edited by: Fick RB Jr, Jardieu PM. 2002, New York: Marcel Dekker, 191-233.
Fahy JV, Fleming HE, Wong HH: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997, 155: 1828-34.
Boulet L-P, Chapman KR, Cote J: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med. 1997, 155: 1835-40.
Fahy JV, Cockcroft DW, Boulet L-P: Effect of aerosolised anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med. 1999, 160: 1023-7.
Casale TB, Bernstein IL, Busse WW: Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol. 1997, 100: 110-21. 10.1016/S0091-6749(97)70202-1.
Milgrom H, Fick RB, Su JQ: Treatment of allergic asthma with monoclonal anti-IgE antibody, rhuMAb-E25 study group. N Engl J Med. 1999, 341: 1966-73. 10.1056/NEJM199912233412603.
Busse W, Corren J, Lanier BQ: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001, 108: 184-90. 10.1067/mai.2001.117880.
Soler M, Matz J, Townley R: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001, 18: 254-61. 10.1183/09031936.01.00092101.
Haahtela T, Jarvinen M, Kava T: Effects of reducing or discontinuing inhaled budes-onide in patients with mild asthma. N Engl JMed. 1994, 331: 700-5. 10.1056/NEJM199409153311103.
Selroos O, Pietinalho A, Lofroos AB, Riska H: Effect of early vs. late intervention with inhaled corticosteroids. Chest. 1995, 108: 1228-34. 10.1378/chest.108.5.1228.
Coyle AJ, Le Gros G, Bertrand C: Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am J Respir Cell Mol Biol. 1995, 13: 54-9.
Henderson WR, Chi EY, Maliszewski CR: Soluble IL-4 receptor inhibitors airway inflammation following allergen challenge in a mouse model of asthma. J Immunol. 2000, 164: 1086-95.
Tony HP, Shen BJ, Reusch P, Sebald W: Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and inter-leukin-13-dependent response in T-cells and B-cells with high efficiency. Eur J Biochem. 1994, 225: 659-65. 10.1111/j.1432-1033.1994.00659.x.
Tanaka H, Nagai H, Maeda Y: Effect of anti-IL-4 and anti-IL-5 antibodies on allergic airway hyperresponsiveness in mice. Life Sci. 1998, 62: 169-74. 10.1016/S0024-3205(98)00047-2.
Borish LC, Nelson HS, Lanz MJ: Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomised, placebo-controlled trial. Am J Respir Crit Care Med. 1999, 160: 1816-23.
Borish LC, Nelson HS, Corren J: Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001, 107: 963-70. 10.1067/mai.2001.115624.
Parameswaran K, Inman MD, Watson RM: Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers. Can Respir J. 2000, 7: 313-9.
Portanova JP, Christine LJ, Rangwala SH: Rapid and selective induction of blood eosinophilia in guinea pigs by recombinant human interleukin 5. Cytokine. 1995, 7: 775-83. 10.1006/cyto.1995.0093.
Leckie MJ, ten Brinke A, Khan J: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000, 356: 2144-8. 10.1016/S0140-6736(00)03496-6.
Lee Y, Fu C, Chiang B: Administration of interleukin-12 exerts a therapeutic instead of a long-term preventive effect on mite Der p I allergen-induced animal model of airway inflammation. Immunology. 1999, 97: 232-40. 10.1046/j.1365-2567.1999.00768.x.
Bryan SA, O'Connor BJ, Matti S: Effects of recombinant human interleukin-12 on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet. 2000, 356: 2149-53. 10.1016/S0140-6736(00)03497-8.
Bechard D, Scherpereel A, Hammad H: Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001, 167: 3099-106.
Papp K, Bissonnette R, Krueger JG: The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol. 2001, 45: 665-74. 10.1067/mjd.2001.117850.
Gauvreau GM, Becker AB, Boulet L-P: The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol. 2003, 112: 331-8. 10.1067/mai.2003.1689.